芫苓消水散联合IL-2腹腔灌注治疗癌性腹水60例
|
摘要
目的:观察芫苓消水散联合IL-2腹腔灌注治疗癌性腹水的临床疗效。方法:将120例癌性腹水患者随机分为对照组和观察组各60例,对照组采用IL-2腹腔灌注治疗,观察组采用IL-2腹腔灌注联合芫苓消水散膏药外敷治疗,治疗2周后比较2组临床疗效、中医证候评分、腹围、腹水深度、24小时尿量、生活质量和毒副反应发生情况。结果:总有效率观察组为85.0%,对照组为65.0%,2组比较差异有统计学意义(P<0.05)。腹围、腹水深度、24小时尿量、KPS评分、中医证候评分治疗前后2组组内比较,差异有统计学意义(P<0.05);治疗后2组组间比较差异也有统计学意义(P<0.05)。观察组除贫血、恶心呕吐外,其余毒副反应发生率均低于对照组,差异有统计学意义(P<0.05)。结论:采用芫苓消水散联合IL-2腹腔灌注治疗癌性腹水患者,效果满意,毒副反应少。
Objective:To observe clinical effects of YuanLing XiaoShui powder and intraperitoneal perfusion of IL-2 in treating malignant ascites. Methods: All 120 patients were randomized into the control group and the observation group, 60 cases each group, the control group adopted intraperitoneal perfusion of IL-2, the observation group used intraperitoneal perfusion of IL-2 and YuanLing XiaoShui powder for external application, after treating two weeks, to compare curative effects, TCM syndrome scores, abdominal perimeter, the depth of ascites, 24 hour urinary volume, quality of life, toxic reactions between both groups. Results: Total effective rate of the control group was 65.0%, lower than 85.0% of the observation group, and the difference showed statistical meaning(P<0.05).The difference had statistical meaning in the comparisons of abdominal perimeter, the depth of ascites, 24 hour urinary volume, KPS scores and TCM syndrome scores within two groups before and after treating(P<0.05); the difference was statistically significant in the comparisons between both groups after treating(P <0.05). The observation group was lower than the control group in the incidences of toxic reactions except anemia, sick and vomiting(P <0.05). Conclusion: YuanLing XiaoShui powder and intraperitoneal perfusion of IL-2 in treating malignant ascites could obtain satisfactory effects with minor toxic reactions.
Objective:To observe clinical effects of YuanLing XiaoShui powder and intraperitoneal perfusion of IL-2 in treating malignant ascites. Methods: All 120 patients were randomized into the control group and the observation group, 60 cases each group, the control group adopted intraperitoneal perfusion of IL-2, the observation group used intraperitoneal perfusion of IL-2 and YuanLing XiaoShui powder for external application, after treating two weeks, to compare curative effects, TCM syndrome scores, abdominal perimeter, the depth of ascites, 24 hour urinary volume, quality of life, toxic reactions between both groups. Results: Total effective rate of the control group was 65.0%, lower than 85.0% of the observation group, and the difference showed statistical meaning(P<0.05).The difference had statistical meaning in the comparisons of abdominal perimeter, the depth of ascites, 24 hour urinary volume, KPS scores and TCM syndrome scores within two groups before and after treating(P<0.05); the difference was statistically significant in the comparisons between both groups after treating(P <0.05). The observation group was lower than the control group in the incidences of toxic reactions except anemia, sick and vomiting(P <0.05). Conclusion: YuanLing XiaoShui powder and intraperitoneal perfusion of IL-2 in treating malignant ascites could obtain satisfactory effects with minor toxic reactions.
引文
[1]易良杰,李升伟,何冬梅,等.加味参苓白术散口服联合白细胞介素-2腹腔灌注治疗卵巢癌相关腹水的临床观察[J].广州中医药大学学报,2017,34(1):31-34.
[2]王志明,庄荣源,陈勇,等.化疗联合腹腔灌注细胞因子诱导的杀伤细胞治疗胃癌腹水[J].中华胃肠外科杂志,2013,16(1):28-31.
[3]陈柏庆,章健,裴俊峰,等.顺铂联合白细胞介素-2治疗消化道肿瘤合并癌性腹水的效果[J].实用医学杂志,2006,22(19):2293-2294.
[4]丁雪梅,李爱民,罗荣城,等.血清IL-2水平与恶性胸/腹水IL-2治疗疗效的关系[J].临床肿瘤学杂志,2003,8(1):14-16.
[5]牛红星.真武汤治疗肝癌癌性腹水疗效观察[J].陕西中医,2015,36(7):841-842
[6]胡忠东,钟美佐,姜斌,等.顺铂和白介素-2腹腔灌注化疗联合射频热疗治疗癌性腹水的疗效观察[J].医学临床研究,2010,27(6):1084-1086.
[7]刘智.顺铂联合白介素-2腹腔灌注治疗癌性腹水疗效观察[J].中国实用医药,2014,9(17):128-130.
[8]孙根林,鲍扬漪.沙利度胺对腹腔转移伴腹水的晚期胃腺癌治疗研究[J].中国医药导报,2011,8(9):66-67.
[9]张彦,阎宁,张扶莉,等.华蟾素注射液联合化疗药物灌注治疗恶性胸腹水疗效观察[J].陕西中医,2014,35(10):1284-1285.
[10]刘佳琪.复方苦参注射液腹腔灌注治疗恶性腹水疗效及安全性观察[J].中国中医药信息杂志,2015,22(2):28-30.
[11]赵月鸣,邢德君.甘露聚糖肽联合化疗药物腹腔灌注治疗老年恶性腹水近期疗效[J].中国老年学杂志,2013,33(23):6023-6024.
[12]杨秀峰,王宏业,杨秀义,等.白细胞介素-2联合艾迪注射液腹腔灌注在恶性腹水源性腹腔间隔室综合征减压后腹水控制中的应用[J].中国基层医药,2017,24(7):961-964.
[13]苏先旭,王辉,马雪莲,等.多西他赛腹腔灌注控制恶性腹水的临床疗效观察[J].四川医学,2012,33(7):1212-1213.
[14]彭玉平,蒋红钢,陈治横,等.经中心静脉导管腹腔灌注IL-2及氟尿嘧啶治疗癌性腹水疗效观察[J].新医学,2012,43(2):97-99.
[15]张红,张向业,潘小平,等.猪苓汤加味治疗癌性腹水临床观察[J].中国中医药信息杂志,2009,16(11):71-74.
[2]王志明,庄荣源,陈勇,等.化疗联合腹腔灌注细胞因子诱导的杀伤细胞治疗胃癌腹水[J].中华胃肠外科杂志,2013,16(1):28-31.
[3]陈柏庆,章健,裴俊峰,等.顺铂联合白细胞介素-2治疗消化道肿瘤合并癌性腹水的效果[J].实用医学杂志,2006,22(19):2293-2294.
[4]丁雪梅,李爱民,罗荣城,等.血清IL-2水平与恶性胸/腹水IL-2治疗疗效的关系[J].临床肿瘤学杂志,2003,8(1):14-16.
[5]牛红星.真武汤治疗肝癌癌性腹水疗效观察[J].陕西中医,2015,36(7):841-842
[6]胡忠东,钟美佐,姜斌,等.顺铂和白介素-2腹腔灌注化疗联合射频热疗治疗癌性腹水的疗效观察[J].医学临床研究,2010,27(6):1084-1086.
[7]刘智.顺铂联合白介素-2腹腔灌注治疗癌性腹水疗效观察[J].中国实用医药,2014,9(17):128-130.
[8]孙根林,鲍扬漪.沙利度胺对腹腔转移伴腹水的晚期胃腺癌治疗研究[J].中国医药导报,2011,8(9):66-67.
[9]张彦,阎宁,张扶莉,等.华蟾素注射液联合化疗药物灌注治疗恶性胸腹水疗效观察[J].陕西中医,2014,35(10):1284-1285.
[10]刘佳琪.复方苦参注射液腹腔灌注治疗恶性腹水疗效及安全性观察[J].中国中医药信息杂志,2015,22(2):28-30.
[11]赵月鸣,邢德君.甘露聚糖肽联合化疗药物腹腔灌注治疗老年恶性腹水近期疗效[J].中国老年学杂志,2013,33(23):6023-6024.
[12]杨秀峰,王宏业,杨秀义,等.白细胞介素-2联合艾迪注射液腹腔灌注在恶性腹水源性腹腔间隔室综合征减压后腹水控制中的应用[J].中国基层医药,2017,24(7):961-964.
[13]苏先旭,王辉,马雪莲,等.多西他赛腹腔灌注控制恶性腹水的临床疗效观察[J].四川医学,2012,33(7):1212-1213.
[14]彭玉平,蒋红钢,陈治横,等.经中心静脉导管腹腔灌注IL-2及氟尿嘧啶治疗癌性腹水疗效观察[J].新医学,2012,43(2):97-99.
[15]张红,张向业,潘小平,等.猪苓汤加味治疗癌性腹水临床观察[J].中国中医药信息杂志,2009,16(11):71-74.